Literature DB >> 8781778

Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.

T Prueksaritanont1, L M Gorham, J H Hochman, L O Tran, K P Vyas.   

Abstract

Drug-metabolizing enzymes were studied in subcellular fractions of dog, monkey, and human small intestines, and in the human adenocarcinoma cell line Caco-2, a commonly used in vitro absorption model. Immunoblot analysis indicated the presence of enzymes related to cytochrome P450 (CYP) 1A1/CYP1A2, CYP2D6, CYP3A, and carboxylesterases (ESs) in human and monkey intestines, and of CYP3A and ES in dog intestines. Catalytically, human and monkey intestines exhibited significant and comparable testosterone 6 beta-hydroxylase, (+)-bufuralol 1'-hydroxylase, and ES activities. In contrast, dog intestine possessed moderate testosterone 6 beta-hydroxylase, much lower ES, and undetectable bufuralol hydroxylase activities. In addition, low tolbutamide methylhydroxylase activity was observed in human and monkey intestines, but not in dog intestines. Of the phase I enzymes investigated, only ES was detected immunologically and functionally in Caco-2 cells. With respect to phase II enzymes, human and monkey intestines contained relatively high intestinal glucuronyltransferase, N-acetyltransferase (NAT), sulfotransferase, and glutathione S-transferase activities. Except for NAT, all phase II enzymes studied were detectable in dog intestines. In Caco-2 cells, acetaminophen sulfation activity was below the limit of detection, whereas all other conjugating activities were evident. Studies of enzyme kinetics and inhibition by known inhibitors of testosterone 6 beta-hydroxylase activity, the major intestinal mono-oxygenase in all species, revealed some similarities between the responsible enzymes. Comparative studies with human liver microsomes suggested the possible involvement of CYP3A enzymes in the intestinal catalysis of testosterone 6 beta-hydroxylation similar to those observed with human hepatic CYP3A. Further studies on ESs, however, revealed multiplicity and species and/or tissue differences in the microsomal and cytosolic enzymes. Based on kinetic studies, monkey intestines and Caco-2 cells possessed NAT activities, with properties similar to those in human intestine and liver. Overall, the results demonstrated that both the preparations of small intestines and Caco-2 cells exhibited significant drug-metabolizing enzyme activities, although several differences were noted between the intestinal enzymes in the animals or in the Caco-2 cells and those found in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781778

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  34 in total

Review 1.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Physicochemical properties and transport of steroids across Caco-2 cells.

Authors:  Fried Faassen; Jan Kelder; Johan Lenders; Rob Onderwater; Herman Vromans
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

3.  Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors.

Authors:  Timo Korjamo; Jukka Mönkkönen; Jouko Uusitalo; Miia Turpeinen; Olavi Pelkonen; Paavo Honkakoski
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

4.  Loss of orally administered drugs in GI tract.

Authors:  Yogeshkumar Nanasaheb Gavhane; Adhikrao Vyankatrao Yadav
Journal:  Saudi Pharm J       Date:  2012-04-20       Impact factor: 4.330

5.  Species differences in stereoselective hydrolase activity in intestinal mucosa.

Authors:  Y Yoshigae; T Imai; A Horita; H Matsukane; M Otagiri
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

6.  Permeation of roxarsone and its metabolites increases caco-2 cell proliferation.

Authors:  Gladys S Bayse; Latanya P Hammonds-Odie; Kimberly M Jackson; Deidre K Tucker; Ward G Kirlin
Journal:  Adv Biol Chem       Date:  2013-08

7.  Transport of thalidomide by the human intestinal caco-2 monolayers.

Authors:  Shufeng Zhou; Yan Li; Phillip Kestell; Peter Schafer; Eli Chan; James W Paxton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

8.  Transport and metabolism of some cationic ubiquinone antioxidants (MitoQn) in Caco-2 cell monolayers.

Authors:  Yan Li; J Paul Fawcett; Hu Zhang; Ian G Tucker
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

9.  An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine.

Authors:  Brendan M Johnson; William N Charman; Christopher J H Porter
Journal:  AAPS PharmSci       Date:  2002

10.  Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.

Authors:  Vibeke Andersen; Natalie Pedersen; Niels-Erik Larsen; Jesper Sonne; Steen Larsen
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.